That’s basically my understanding of how the terms are usually defined as well. Basically, a partner is defined by participation in the development of the drug along the way. I was - and am - mostly just curious why you thought that REGN would be a good partner, but not a good commercialization “partner” (for lack of a more precise term)? Seems to me that they’d be a good fit, was just wondering if I’m missing something. I guess I would imagine that a partnership arrangement, as we’re both defining it, could have either entity handle the commercialization as deemed appropriate.

No worries either way, again just curious. Have a good weekend!